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Abstract Objectives: Inhaled corticosteroids (ICS) are
widely used in the treatment of asthma. We studied the
suspected adverse drug reactions (sADRs) reported during
the use of ICS in the Netherlands. Methods: In the
Netherlands, health professionals and patients can report
suspected ADRs to the Pharmacovigilance Centre Lareb.
All reported sADRs on ICS were categorised and assessed
as to whether these were likely to be associated with use of
the steroid. Age and gender adjusted Reported Odds
Ratios (RORs) and Naranjo Scores (NS) were computed
for sADRs reported more than 3 times. Results: Since
1984, sADRs of ICS were reported in 89 children (mean
age 6 years), 48 (54%) were boys. Suspected drugs were
fluticasone in 46 children (52%), budesonide in 21 (24%),
and beclomethasone in 22 cases (24%). Psychiatric
symptoms were reported in 19 children (21%; ROR 3.8,
NS 3.6), growth retardation in 6 children (7%; ROR 47.8,
NS 3.0) and rashes in 6 cases (7%; ROR 0.7, NS 2.4).
There were 7 reports (8%; ROR 2.1, NS 3.4) concerning
abnormalities of the teeth, 4 reports of alopecia (4%; ROR
3.3, NS 3.5), and 3 reports of hirsutism and hypertrichosis
(NS 4.0). Non-fatal adrenal insufficiency was reported
once. Conclusions: Alteration of behaviour was the most
frequently reported sADR. There are more indications that
alterations of behaviour could be a real sADR of ICS.
Non-fatal adrenal insufficiency was the only reported
possible life threatening sADR. The association of hyper-
trichosis and teeth abnormalities after ICS in children has
not been reported in the literature before.
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Introduction
Inhaled corticosteroids (ICS) are the mainstays in the
treatment of asthma in both children and adults. Several
guidelines advise the early introduction of ICS in mainte-
nance treatment of persistent asthma [2, 3, 11]. However, as
ineverycategoryofdrugs,adversedrugreactionsmayoccur.
Well-known adverse drug reactions after ICS in children
include growth retardation, adrenal suppression, hoarseness,
oral candidiasis, and laryngeal irritation [16]. These are
included in the Summary of Product Characteristics.
Other less prevalent adverse effects have been recog-
nised and are included in reference textbooks and sources
such as Meyler’s Side Effects of Drugs and Micromedex
[4, 5].
To broaden the knowledge of ADRs after ICS in children
we studied the reports of suspected adverse drug reactions
(sADRs) in the Netherlands. We wanted to know which
sADRs were reported the most frequently. Furthermore, we
were interested to find reports of new sADRs and whether
life-threatening sADRs were reported.
Methods
For this study, we used the database of the Dutch
Pharmacovigilance Centre Lareb. Health professionals and,
since2004,patientsorcaregiverscanreportsADRstoLareb,
which collects and analyses sADRs, voluntarily reported, on
behalf of the Dutch Medicines Evaluation Board.
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terminology and the anatomical therapeutical chemical
(ATC) classification drug coding system respectively, and
subsequently filed in a database. This database was
searched for reported sADRs by ICS in children younger
than 17 years of age.
Computations
The relationship between ICS and reported sADRs were
evaluated mathematically by computing the Reporting
Odds Ratios (RORs) and de Naranjo Scores (NSs). The
ROR compares the frequency of the reported sADR for a
certain drug with the frequency of reports of that adverse
effect for all other drugs in the Pharmacovigilance
database. A statistically significant ROR might be an
indication for a possible causal relationship between the
drug and the reported complaints. The RORs and 95%-
confidence intervals (95%CI) were calculated in a case/
non-case design [21]. RORs adjusted for age and gender
were calculated by means of logistic regression analysis.
Another way to get an impression of the probability of a
causal relationship is the Naranjo Score (NS). The NS
evaluates the causality of drugs on an individual basis [22].
The NS varies from 0, indicating no association, to 10,
indicating a proven causal association. Originally, the NS
was developed for evaluation of sADRs in hospitalised
patients. Because in outpatients the evaluation of sADRs is
limited, the NS of sADRs in outpatients is generally lower
than in hospitalised patients. A NS from 1 to 4 is
considered to reflect a possible association in outpatients.
Both the ROR and NS were computed when a sADR was
reported at least 4 times. For computations and statistical
analysis we used SPSS (version 11.0).
Results
In the period of June 1984–October 2004, Lareb received
46,314 reports of sADRs. Of these, 2,499 reports (5.4%)
concerned individuals younger than 17 years of age. In 89
of these 2,499 children (3.6%) one or more sADRs after
ICS were reported. The median age of the children was 6
years and 48 (54%) of them were boys. Suspected drugs
were fluticasone in 46 children (52%), budesonide in 21
(24%), beclomethasone in 19 cases (21%), and beclometh-
asone fine particles in 3 (3%).
Psychiatric symptoms, belonging to the system and
organ class ‘psychiatric symptoms’ within the MedDRA
classification system, were reported in 19 cases (21%). The
symptoms included agitation and hyperactivity in 10 cases,
aggression in 7 children and anxiety in 2. The ROR was 3.8
(95%C.I. 2.2–6.4), which is statistically significant. The
mean NS was 3.6. We compared the group of children on
whom a psychiatric sADR was reported with the group of
children with other sADRs reported during the use of ICS.
There were no gender differences, but the children on
whom a psychiatric sADR was reported were statistically
significantly younger (4.7 vs 6.6 years, p=0.01). Although
the mean daily doses prescribed in the group of children
with psychiatric symptoms was higher (318 µg vs 252 µg),
this was not statistically significant. Only one patient
received a dose higher than advised in the guidelines. This
6-year-old girl received a dose of 800 microgram
budesonide daily via a pMDI and spacer. The drugs related
to psychiatric symptoms did not differ from the distribution
of the drugs associated with other sADRs.
Non-fatal adrenal suppression was reported in a 10-year-
old girl, who received inhaled fluticasone (500 microgram
daily) and nasal beclomethasone (100 µg daily).
There were a few sADRs never described before. Teeth
discoloration and caries were reported in 7 children, the
ROR was 2.1 (95%C.I. 1.0–4.8) and the NS was 3.4.
Alopecia had been reported four times, the ROR was 4.2.
Hirsutism and hypertrichosis were reported in 3 patients
and the mean NS was 4.
Table 1 Numbers, crude and age and gender adjusted reporting odds ratios, and Naranjo scores of the suspected adverse drug reactions












Symptoms 19 160 3.8 (2.2–6.5) 3.8 (2.2–6.4)* 3.6
Teeth abn. 7 95 2.1 (0.9–4.6) 2.1 (1.0–4.8) 3.4
Growth retardation 6 83 34.7 (10.4–116.2) 47.8 (11.7–176.1)* 3.0
Rash 6 83 0.7 (0.3–1.5) 0.7 (0.3–1.6) 2.4
Alopecia 4 34 3.3 (1.1–9.5) 4.2 (1.4–12.5)* 3.5
Headache 4 64 1.7 (0.6–4.9) 1.9 (0.7–5.3) 4.0
ADR = adverse drug reaction; ICS = inhaled corticosteroids, ROR = reporting odds ratio, NS = Naranjo score, 95%C.I.=95% confidence
interval; abn. = abnormalities
*statistically significant
344Growth retardation was reported in 6 patients. The ROR
was 47.8 (95%C.I. 11.7–176.1) the NS was 3.0. Rashes
were reported in 6 children, the ROR was 0.7, headache
was reported 4 times, the ROR was 1.9, and both are not
statistically significant. Table 1 summarises the sADRs,
reported at least 4 times after ICS in children.
Other sADRs included: urticaria, cough, insomnia,
epistaxis, facial oedema, excessive weight gain, abdominal
pain, fatigue, diarrhoea, dyspnoea, eczema, hoarseness,
bronchorrhea, bruising of the skin, amenorrhea, anorexia,
cataract, gingivitis, mydriasis and pruritus.
Discussion
The efficacy of ICS in the treatment of persistent asthma is
beyond any doubt [2, 3, 11]. However, like every drug they
may cause ADRs. We were struck by the high frequency of
reports of psychiatric alterations after ICS. The high NS
and the adjusted ROR argue for a real association between
psychiatric alterations after ICS in normal doses. As far as
we know, the association between ICS and psychiatric
sADRs has not studied extensively before.
It is well established that oral steroids can cause psychic
alterations in adults and children [4]. Kayani compared oral
courses of 1 mg/kg and 2 mg/kg prednisolone in asthmatic
children and found significantly more anxiety, hyperactiv-
ity and aggressive behaviour in patients receiving the
higher dose [15]. In 1988, a 9-year-old boy who exerted
hyperactive behaviour after budesonide 200 micrograms
daily was described [19]. More recently, Hederos described
a group of 60 children of whom 9 (15%) experienced
psychiatric side effects after high doses of budesonide [14].
Bender compared beclomethasone with theophylline, but
found no differences [6]. However, they did not give
absolute figures. Moreover, these children were 6–17 years
old and most of the reports on psychiatric alterations in our
study concerned children under the age of 5.
Elias exposed rats to inhaled budesonide and found a
significant effect on learning and motivation functioning
[10]. This is compatible with the concept that ICS “cross
the borders between inhaled air and brain”.
An alternative explanation of altered behaviour after ICS
is that untreated asthmatic children could be hampered in
their activity and therefore exert “hyperactivity” when their
asthma is treated sufficiently. As far as we know, this has
never been studied.
It is also possible that psychiatric alterations occur as a
result of other concomitant medications. It is widely
believedthat beta-agonists leadto hyperactivity.Hajikoumi
et al. [12] studied this in 19 pre-school children in a blinded
crossover study, but did not find a difference between 5 mg
salbutamol, administered via an oxygen driven nebuliser
and placebo. However, they studied the effect of only one
dose in children with or without asthma.
Finally, an alternative explanation could be that asthma
by itself leads to behavioural problems. Indeed, in a recent
study it was demonstrated that children who developed
asthma had more behavioural problems than children who
never wheezed [7]. Also, in a review McQuaid et al. [18]
demonstrated that behavioural problems were more fre-
quent in children with asthma than in controls. However,
the high ROR and NS of the psychiatric symptoms argue
for a real effect of ICS.
Taken together, we believe that one should be aware of a
possible negative influence of ICS on psychiatric function-
ing of a child and that therefore a thorough study is
warranted.
We did not find any reports of deaths after ICS
treatment. A recent British study described two cases
with fatal outcome in which ICS were involved [8]. Neither
details of the mechanism of how the drugs contributed to
the death of the children nor details were given. Therefore
the role of ICS in these cases is difficult to assess.
Adrenal suppression is a potential life-threatening event
and was reported only once during the study period in the
Netherlands. It could be that adrenal suppression is not
recognised and therefore is not reported. In a national
survey in the United Kingdom of the occurrence of adrenal
crises during ICS, 33 periods of adrenal crises in children
from 3–10 years (mean 6 years) were identified. In 30
cases, fluticasone had been used and, in 27, at least one
course of oral steroids had been used in the previous years.
The doses of ICS were higher than generally recommended
for children (mean daily dose 980 µg) [23]. Children
receiving fluticasone in doses exceeding 400 µg daily and
who have been treated recently with a course of oral
steroids seem to be vulnerable.
There were some unexpected reported sADRs. Adverse
effects on teeth (discoloration and caries) after ICS have
not been reported before. Because discoloration of teeth
has been described after the use of antibiotics, such as
amoxicillin, and we do not have data on prior medication
use, it could be that antibiotics might have played a role
[20]. Although the NS is high, the relatively low ROR
argues against an association. The relationship between
sADR of ICS on teeth therefore remains unclear.
Hirsutism and hypertrichosis have never been reported
to be associated with ICS in children before, although they
are described after oral corticosteroids in adults [4]. The
relatively high NS suggests a possible association.
Six reports to Lareb concerned a negative effect on
growth. The high ROR and NS demonstrate the usefulness
of these parameters. The effect of ICS on growth has been
studied extensively. Although in children treated for years
with ICS the final adult height did not differ from the
expected height [1], we believe it is necessary to check the
growth of children on ICS regularly.
Hoarseness was reported once to Lareb, whilst it was
found in 14% of a French group of asthmatic children on
ICS [9]. Although a frequency between 4 and 13% of oral
candidiasis in patients on ICS is reported [13], Lareb did
not receive any report concerning candidiasis.
Rashes were reported 6 times, but the ROR was not
statistically significantly increased. As far as we know, the
frequency of dermatological side effects in children has
never been studied. In adults, negative effects on the skin
have been well recognised. Mak [17] studied 202 asthmatic
345adults on ICS and found that 47% of them had easy
bruising versus 22% in a control group. Not surprisingly,
risk factors were longer duration of treatment, older ages,
and the use of higher doses of ICS. In children, these risk
factors do not occur.
The frequency of other sADRs is too low for conclu-
sions. The distribution of sADR and drugs involved does
not differ from the distribution of prescription of individual
ICS. In 2002, of 2,592 prescriptions for ICS in a
representative Dutch population, 29% were for beclometh-
asone, 17% for budesonide and 54% for fluticasone
(E. Schirm, personal communication).
A study like this has some limitations. First, in the
Netherlands, reporting sADRs is voluntary, therefore not
all sADRs, especially the better known ones, will be
reported. This can lead to underreporting but this is
inevitable in this kind of study. On the other hand, because
of the voluntary nature of reporting, the persons who will
report obviously have no other drive than being concerned
about possible associations. Secondly, we used the NS to
evaluate the association between the use of ICS and sADRs
in outpatients. However, the NS is the only available
measure for causality in outpatients. It should be kept in
mind that neither the NS nor the ROR prove causality, but
should merely be regarded as a sign of a possible
association.
Based on the outcome of this study, we conclude that
apparently there is an association between the use of ICS
and behavioural changes in young children. Alteration of
behaviour (agitation, hyperactivity) was the most fre-
quently reported sADR of ICR in children. Adrenal
insufficiency was the only reported potentially life-
threatening sADR. The association with alopecia, hyper-
trichosis and hirsutism has not been described before and
neither have dental abnormalities been reported.
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